Eugia Pharma Receives USFDA Approval for Hydralazine Hydrochloride Injection USP, 20 mg/mL Single-Dose Vials

Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Hydralazine Hydrochloride Injection USP, 20 mg/mL Single-Dose Vials.

Indications for this product include:

• It is used in severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure.

Refer to package insert for full prescribing information.